Hikal share price caught fire today, February 12, 2026. The stock jumped 14.43% to ₹218.20 by 10:30 AM IST, hitting a high of ₹219.30. After hovering near its 52-week low of ₹177, this sharp move feels like a much-needed relief for shareholders. Investors rushed in on fresh news from yesterday’s Q3 results.
Hikal Share Price Today: Quick Snapshot
| Metric | Details |
|---|---|
| Current Market Price | ₹218.20 |
| Percentage Change | +14.43% |
| Today’s High / Low | ₹219.30 / ₹194.47 |
| Previous Close | ₹190.68 |
| 52-Week High / Low | ₹456.75 / ₹177.35 |
Why Hikal Share Price Jumped Today
The rally kicked off after Q3 FY26 earnings came out on February 11. Even with a net loss, two big positives changed the mood.
First, the Board announced a 10% interim dividend – ₹0.20 per share. The record date is February 17, 2026. Anyone holding shares by then qualifies. Dividend news always brings quick buying, and today was no different.
Second, revenue held up well. Operations grew 10.4% year-on-year to ₹4,943 million. The Pharmaceutical segment led with a solid 15% rise, showing demand is still there despite tough times.
The stock had sunk to its yearly low recently. Many saw today’s jump in Hikal share price as value hunters stepping in plus short-covering after the bottom looked set.
On charts, the stock crossed above its 5-day and 20-day moving averages. That triggered buy signals for traders watching for a bounce.
Hikal Share Price Rally: Q3 FY26 Numbers Breakdown
The quarter gave a mixed picture:
- Net loss: ₹59 million (vs profit of ₹173 million last year).
- Big hit came from a one-time ₹380 million charge due to new Labour Codes (extra gratuity and leave provisions).
- Pharma revenue: ₹3,373 million (+15% YoY).
- Crop Protection revenue: ₹1,570 million (+1.7% YoY).
Without that exceptional item, the bottom line would have looked much better.
Also Read: Gandhi Talks Box Office Collection Day 13: Vijay Sethupathi’s Silent Film Stays Quiet
Challenges Still Facing Hikal Share Price
Good news today doesn’t erase the hurdles:
- USFDA warning letter on the Jigani plant (from August 2025) keeps delaying some customer orders in Pharma.
- Ongoing review of past revenue recognition issues (some employees changed documents).
- Auditors gave a modified opinion – full impact of probes isn’t clear yet in the books.
These risks mean Hikal share price could stay volatile until clarity comes.
What Analysts Say About Hikal Share Price
Views are split but lean hopeful long-term. HDFC Securities and ICICI Direct stay positive on the CDMO business and API pipeline recovery. Targets range from ₹302 to ₹324.
Most see today’s surge in Hikal share price as a tactical move – dividend grab plus revenue stability – rather than a full turnaround.
The company remains a key player in contract manufacturing for pharma and crop protection. If regulatory issues ease and orders flow back, there could be more upside.
For now, Hikal share price feels like it found a temporary floor. Dividend chasers got their win today, and bargain hunters joined in. Watch closely for next updates on the USFDA and internal review – they’ll decide if this bounce holds or fades.
Disclaimer: This content is for informational purposes only and should not be considered professional [financial/legal/medical] advice. Always seek the advice of a qualified professional before making any decisions based on this information.
Sources & References
- Screener.in
- Official Exchange Filings via BSE/NSE.
- IndiaIPO.in.
- Hikal Ltd Official Announcement
Yogesh Kolhe is a business and market news writer covering the share market, company earnings, and gold and silver price movements, with a strong focus on the automobile sector. A Mechanical Engineering graduate with 5 years of share market experience, he provides data-driven, reliable insights into market and industry trends.
